MedTrace Logo

Project CADENCE (CAncer Detected Early caN be CurEd)

NCT05633342 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2023-03-20

No results posted yet for this study

Summary

With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be dysregulated during disease progression. Combining the power of multi-omic cancer biomarkers, the investigators hypothesize that the sensitivity and specificity of MiRXES MCST can be significantly improved compared to existing multi-cancer diagnostic tests.

In this study, the investigators propose to develop and validate blood-based, multi-cancer screening tests through a multi-omics approach.

Conditions

Sponsors & Collaborators

  • MiRXES Pte Ltd

    lead INDUSTRY

Principal Investigators

  • Cheng He, PhD · MiRXES Pte Ltd

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-07
Primary Completion
2024-12-31
Completion
2025-05-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633342 on ClinicalTrials.gov